Trials / Recruiting
RecruitingNCT06957314
A Study of Hospital-at-Home for People Receiving Tarlatamab
MATCHES-Novel: MAking Telehealth Delivery of Cancer Care at Home Effective and Safe for Novel Therapies: A Hospital-at-Home Model for Tarlatamab Delivery
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 70 (estimated)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to find out whether a Hospital-at-Home (HaH) program is a more efficient way to monitor people's health after receiving tarlatamab than monitoring in the hospital (inpatient).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Hospital-at-Home/HAH | After discharge, a SeniorCare community paramedic will provide a home visit to the participant's home or residence |
Timeline
- Start date
- 2025-04-23
- Primary completion
- 2028-04-23
- Completion
- 2028-04-23
- First posted
- 2025-05-04
- Last updated
- 2026-03-27
Locations
7 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT06957314. Inclusion in this directory is not an endorsement.